4.4 Article

In vivo and in vitro estrogenic activity of the antidepressant fluoxetine

Journal

REPRODUCTIVE TOXICOLOGY
Volume 34, Issue 1, Pages 80-85

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.reprotox.2012.04.001

Keywords

Depression; Fluoxetine; Endocrine disruption; Uterotrophic assay; Hershberger assay; Reporter gene assay; Estrogenic activity

Funding

  1. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
  2. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Ask authors/readers for more resources

Recent years have seen an increase in the use of antidepressant drugs, especially fluoxetine (FLX), in sensitive populations, such as pregnant and lactating women. Although some evidence suggests a possible endocrine action of FLX, no specific studies have been performed to investigate this hypothesis. In the present study, we investigated the possible (anti)androgenic and (anti)estrogenic actions of FLX using Hershberger, uterotrophic (0.4, 1.7, and 17 mg/kg), and reporter gene (7.6-129 mu M) assays. In the Hershberger assay, no differences were observed in androgen-dependent organ weights. However, the uterotrophic and gene reporter assays indicated a possible estrogenic action of FLX. Uterine weight increased in the 1.7 and 17 mg/kg/day groups in the 3-day uterotrophic assay in immature rats. Additionally, noncytotoxic concentrations of FLX induced estrogenic responses and increased the estrogenic response of estradiol in MCF-7 breast cancer cells transfected with luciferase. (C) 2012 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available